
How stars die: White dwarfs, neutron stars and supernovae
The stars in the sky seem to shine forever, but they too are subject to lifespans determined by their mass and internal physics. Some last for billions of years and others are transitory in comparison, with far shorter lifetimes.
Regardless of duration, all stars survive by maintaining a balance between two competing forces: the inward pull of gravity and the outward pressure produced by nuclear energy. In the dense core of a star, nuclear fusion converts hydrogen into helium. This process occurs because the extremely high temperatures and pressures force atomic nuclei — normally repelled by their positive charges — to collide and merge, releasing enormous energy. That energy heats the surrounding gas, generating thermal and radiation pressure that resists gravitational collapse.
This elegant explanation of how stars shine wasn't always known. It was only in 1938, while riding a train to Ithaca, New York, that German-American physicist Hans Bethe scribbled down the equations describing how nuclear fusion powers stars — a breakthrough that won him the Nobel Prize and solved one of astrophysics' most pressing mysteries.
But even fusion has its limits. When a star's fuel is exhausted, gravity takes over — and then the nature of its death depends entirely on its mass.
Stars with masses similar to or less than our Sun meet their end through a relatively gentle transformation. Once the core exhausts its hydrogen, fusion slows, and gravity causes the core to contract. As it contracts, it heats up. When it crosses a critical temperature threshold — about 100 million Kelvin — helium fusion begins, converting helium into carbon and oxygen.
Meanwhile, the surrounding shell of hydrogen just outside the core also heats up and reignites in a thin layer. This shell-burning dumps energy into the star's outer layers, causing them to expand dramatically. The star becomes a red giant—swollen, cooler on the surface, but far more luminous than before.
Eventually, the star cannot sustain further fusion. The outer layers are gently expelled into space, forming a glowing planetary nebula, while the core is left behind as a white dwarf: a hot, dense object roughly the size of Earth, composed mostly of carbon and oxygen. About 95% of stars in an average galaxy like our Milky Way end up as white dwarfs.
The Sun, too, will follow this path. In about five billion years, it will swell into a red giant, likely engulfing Mercury and Venus, perhaps even Earth. It will shed its outer layers and leave behind a white dwarf at its center— a slow, fading remnant that will radiate heat into space for billions of years. No explosion will mark the Sun's end — only a quiet dimming.
But even quiet deaths have their boundaries. In 1930, a young Indian physicist named Subrahmanyan Chandrasekhar, while sailing to England, calculated that a white dwarf above a certain mass — about 1.4 times that of the Sun — could not support itself against gravity. Beyond this Chandrasekhar limit, collapse would be inevitable.
His idea, initially ridiculed, later laid the foundation for our modern understanding of black holes and won him the Nobel prize decades later.
For stars more than eight times the mass of the Sun, the end is anything but quiet. These stars can reach the extreme core temperatures required to fuse progressively heavier elements — carbon, oxygen, silicon — all the way up to iron.
At this point, the physics changes dramatically. The fusion of iron does not release energy; instead, it consumes it. Without any source of pressure to oppose gravity, the core collapses in on itself within seconds. It becomes incredibly dense, forming a neutron star, or if massive enough, a black hole.
Meanwhile, the outer layers of the star, still falling inward, slam into the stiffening core and rebound outward. This violent interaction, combined with a flood of escaping neutrinos and thermal energy, drives a powerful supernova explosion. The result is one of the most luminous and energetic events in the universe — a dying star momentarily shining brighter than an entire galaxy.
Fusion in stars builds elements only up to iron. But the heavier elements—gold, uranium, iodine—are forged in the final moments of a star's life. The heat, pressure, and rapid neutron bombardment during a supernova enable a cascade of nuclear reactions that form these rare, heavy elements.
The explosion disperses them across the galaxy, enriching the gas clouds that will form the next generation of stars and planets. Much of Earth's matter —including the iron in our blood and the calcium in our bones — originated in the fiery death of long-gone stars.
Not all stellar explosions require high-mass stars. In binary systems, a white dwarf can siphon material from a nearby companion. If it accumulates enough mass, it reaches a tipping point, triggering a runaway thermonuclear explosion — a type Ia supernova — that obliterates the star. These explosions serve as cosmic mile-markers for measuring the expansion of the universe, and they too help enrich the interstellar medium with heavy elements.
Whether a star dies with a whisper or a bang, its death is not just an ending — it is an act of cosmic renewal. The materials scattered by dying stars seed new solar systems, new worlds, and, ultimately, the conditions for life itself.
We are built from atoms forged in the hearts of stars — refined in their lifetimes and released in their deaths. In every stellar ending lies the promise of a beginning.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hindustan Times
4 hours ago
- Hindustan Times
Global cooperation on AI necessary but 'difficult' in today's geopolitical context: Google Deepmind CEO
Artificial intelligence pioneer and head of Google's Deepmind, Demis Hassabis on Monday said that greater international cooperation around AI regulation was needed but "difficult" to achieve "in today's geopolitical context". At a time when AI is being integrated across all industries, its uses have raised major ethical questions, from the spread of misinformation to its impact on employment, or the loss of technological control. At London's South by Southwest (SXSW) festival on Monday, Hassabis, who has won a Nobel Prize in Chemistry for his research on AI, also addressed the challenges that artificial general intelligence (AGI) -- a technology that could match and even surpass human capability -- would bring. "The most important thing is it's got to be some form of international cooperation because the technology is across all borders. It's going to get applied to all countries," Hassabis said. "Many, many countries are involved in researching or building data centres or hosting these technologies. So I think for anything to be meaningful, there has to be some sort of international cooperation or collaboration and unfortunately that's looking quite difficult in today's geopolitical context," he said. At Paris's AI summit in February, 58 countries -- including China, France, India, the European Union and the African Union Commission -- called for enhanced coordination on AI governance. But the US warned against "excessive regulation", with US Vice President JD Vance saying it could "kill a transformative sector". Alongside the US, the UK refused to sign the summit's appeal for an "open", "inclusive" and "ethical" AI. Hassabis on Monday advocated for the implementation of "smart, adaptable regulation" because "it needs to kind of adapt to where the technology ends up going and what the problems end up being".


Time of India
6 hours ago
- Time of India
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy
Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda. The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on experimental cancer treatments and show that its success as Pfizer 's COVID-19 vaccine partner was not a one-off achievement. It also underscores a push across the pharma sector to master a new dual mechanism of action in oncology that activates the immune system - similar to an established drug class including Merck & Co's Keytruda - but which also cuts a tumour's blood supply. BioNTech's German-listed shares surged 16.7% by 1236 GMT to a six-week high. The two companies said in separate statements that the U.S. group will co-develop and co-commercialize BioNTech's drug, BNT327, for multiple solid tumour types. Live Events BioNTech's CEO and co-founder Ugur Sahin said the collaboration will serve "to accelerate and broadly expand BNT327's development to fully realize its potential." The companies said in presentation slides that Bristol Myers was bringing global networks in clinical development and manufacturing to the partnership, among other benefits. BioNTech said in a statement that the partners were seeking to set a new standard of care in the cancer market segment, now dominated by so-called checkpoint inhibitors including Keytruda with $29.5 billion in 2024 sales. Western drugmakers have struck a host of deals to win access to the new drug technology, known as PD-1/VEGF bispecific antibodies, which was pioneered in China. Pfizer last month partnered with China's 3SBio , paying $1.25 billion upfront and up to another $4.8 billion depending on developmental achievements. Merck & Co, whose Keytruda business is under threat from the sector's development push, in November last year licensed an early-stage cancer drug from China-based LaNova Medicines for up to $3.3 billion. "We are now starting to see an industry vote of confidence in the differentiation of this novel mechanism," BMO Capital Markets analysts said in a note. They welcomed BioNTech "partnering with a big pharma name to help manage a broad development plan and potential commercialization". Shares in Instil Bio, which is working with China's ImmuneOnco on a similar compound, soared 24% in U.S. trade on Monday. Summit Therapeutics and China's Akeso have formed another partnership in the development race with a drug candidate called ivonescimab. BioNTech took full ownership of BNT327 through the acquisition of China's Biotheus earlier this year for $800 million upfront and up to $150 million contingent on development achievements. It previously held certain rights in the drug under a 2023 collaboration deal. In addition to an initial payment of $1.5 billion, Bristol plans to pay BioNTech $2 billion in non-contingent anniversary payments through 2028. BioNTech may also earn up to $7.6 billion in development, regulatory and commercial milestones, Bristol said. The companies will share global profits and losses from the drug equally, and joint development and manufacturing costs will also be shared on a 50/50 basis, with some exceptions. BNT327 is being tested as a first-line treatment in extensive stage small cell lung cancer and non-small cell lung cancer. More than 1,000 patients have been treated with the drug to date. Economic Times WhatsApp channel )


Time of India
7 hours ago
- Time of India
The age-reversing routine of this 56-year-old woman is beating million-dollar biohacks by a wide margin- here's what she does
Julie Clark is turning heads online with a simple, $4-a-day age-reversing routine . She is 56 years old, but her biological age is only 36. She is now the second oldest person in the world. Her method is natural, useful, and much cheaper than high-tech methods. One of the most successful and well-liked individuals attempting the $2 million a year process is American millionaire and entrepreneur Bryan Johnson. Bryan Johnson will most probably be envious of this woman's habit of reversing her age. Her way of life includes getting up early, working out in a balanced way, eating clean, taking few supplements, and sticking to strict sleep schedules. This is a realistic and effective alternative to million-dollar longevity programs like Bryan Johnson's. This strategy provides a less complicated and more affordable option to exorbitantly priced biohacking techniques. ALSO READ: Jonathan Joss, voice of John Redcorn from King of the Hill, tragically shot and killed at 59 Live Events Best-selling author and health researcher Craig Brockie recently shared information about Julie Clark, a 56-year-old woman whose biological age is 36, on X. According to Brockie, Clark was surpassing Bryan Johnson and placing second on the global longevity board, redefining the science of aging. Why is she being compared to Bryan Johnson? For far too long, Bryan Johnson has been the well-known spokesperson for reverse aging . But his regimen, known as the Blueprint, consists of a strict vegan diet, numerous supplements, intense exercise, and other procedures that cost an estimated $2 million a year. A shining alternative in this case is Clark's reverse aging regimen, which is easy to follow, inexpensive, and simple, and produces surprisingly good results. What does the term "reverse ageing" mean? Age reversal, or reverse ageing, slows the body's natural aging process and physiological changes. Scientists are investigating cellular and molecular interventions to reverse age-related changes, but total reversal is still impossible. Lifestyle changes and treatments have been used to target biological age, which is health and system function. What does her daily routine look like? Brockie shared Clark's anti-aging regimen for optimal health and long-term longevity. Julie Clark's health routine: Morning Routine: • Wakes up between 4-5 AM, makes bed, drinks green tea, and engages in calming activities. • Goes to the gym on weekends for body and mind relaxation. Movement: • Trains six days a week, focusing on lifting and cardio. • Uses compound movements like Romanian deadlifts and split squats. • Focuses on Zone 2 training during cardio. • Ends workouts with a 20-30 minute sauna and a 5-minute cold shower. Diet: • Tracks food intake, aiming for 1 lb of vegetables, half of which are greens, and 100g of protein. • Breakfast includes moringa, fermented greens, collagen, maca, lunch includes veggies with eggs or meat, and dinner includes steak, greens, or sardines. Supplements: • Takes pills of B-complex, fish oil, probiotics, Magnesium, Vitamin D3 + K2, Inositol, Apigenin & L-theanine. Sleep Schedule: • Bedtime is 8, and sleep is 8:30. • Prior to sleep, she takes a long walk with calming music. FAQs How much does Julie Clark's anti-aging regimen cost? Only about $4 per day, significantly less than high-end biohacking programs. What's Julie Clark's secret for looking younger? She attributes her success to regular sleep, exercise, a healthy diet, and mindfulness, all of which are inexpensive treatments.